NxThera Secures $40M in Financing to Market Rezūm System

Maple Grove, Minn.-based NxThera has completed a $40 million round of financing led by Boston Scientific, with current investors Aberdare Ventures, Arboretum Ventures, GDN Holdings and The Ally Bridge Group also participating.

The financing will support the company’s marketing of its Rezūm System — which received FDA clearance in August — to treat benign prostate hyperplasia.

The system allows urologists to treat patients with BPH in a variety of clinical settings, including in urology clinics and surgical centers.

More than half of men over the age of 50 around the globe suffer from BPH symptoms, according to the company. — Michael Cipriano